Via Pharmaceuticals Inc · OTC:VIAP
Via Pharmaceuticals — Corautus Genetics — Roth Capital Partners New York Conference 2004
22 slides from Via Pharmaceuticals's conference presentation, Sep 15, 2004
Slide 1: Roth Capital Partners New York Conference
Roth Capital Partners New York Conference September 15, 2004 Richard E. Otto President and CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and p
Slide 3: Recent Announcement
Recent Announcement ATLANTA, GA, September 8, 2004… Corautus Genetics Inc. (AMEX : CAQ) today announced the commencement of its Phase IIb clinical trial to evaluate the safety and efficacy of Vascular Endothelial Growth Factor-2 (VEGF-2) for the treatment of severe cardiovascular disease. THE GENASI
Slide 4: Coronary Artery Disease Platform
Coronary Artery Disease Platform American Heart Association “Top 10” research advances 2001 Phase I and Phase IIa clinical trials completed for CAD License agreement for VEGF-2 with Human Genome Sciences Inc. (HGSI) $25 million collaboration with Boston Scientific Corp. (BSX) Participation of key op
Slide 5: Peripheral Artery Disease Platform
Peripheral Artery Disease Platform Previous preclinical and Phase I clinical trial data Current Open IND Fast Track Status for reduction of incidents of amputation in patients with Critical Limb Ischemia Orphan Drug Status for Buerger’s Disease Plans for later stage clinical trials Participation of
Slide 6: Convergence of Critical Success Factors
Convergence of Critical Success Factors Unmet medical need in large patient populations Severe coronary artery disease Severe peripheral artery disease Diabetic neuropathy Fortress of intellectual property Major collaborations Initiated manufacturing of VEGF-2 for Phase III and commercialization Suc
Slide 7: Intellectual Property
Intellectual Property Boston Scientific Corporation Human Genome Sciences Inc. Corautus Genetics Inc. Caritas St. Elizabeth’s Medical Center Vical Inc. Corautus believes it has a fortress IP position in cardiovascular gene therapy and that no additional licenses are required for commercialization
Slide 8: Jeffery M. Isner, M.D. & Vascular Genetics Inc.
Jeffery M. Isner, M.D. & Vascular Genetics Inc. ‘No discussion on therapeutic angiogenesis would be appropriate without honoring the person who was clearly the leader in the field. Dr. Jeffery M. IsnerJeff was the consummate Clinician/Scientist and without question the pioneer in this area.’ Cardiol
Slide 9: The Vision – Biologic Revascularization
The Vision – Biologic Revascularization Conventional vs. Regenerative Pharmacologic Treats Symptom Underlying condition unaltered Biologic (Genetic) Treats Cause Underlying condition altered Biologic revascularization may offer superior outcomes in the treatment of refractory angina through patients
Slide 10: Coronary Artery Disease Market Size
Coronary Artery Disease Market Size Conventional “The New Era Regenerative Opportunity MEDICAL THERAPY Nitroglycerin, Beta Blockers, Calcium Antagonists, Statins INTERVENTION PTCA / Stent SURGERY CABG REFRACTORY MYOCARDIAL ISCHEMIA $1 Billion (*) Corautus will deliver naked DNA plasmid through BSX’s
Slide 11: Refractory Myocardial Ischemia
Refractory Myocardial Ischemia Class III-IV refractory angina Cardiac muscle demand for 02 is greater than supply Significant chest pain on minimal or no exertion No proven therapy for Class III-IV refractory angina Poor quality of life Significant demand for effective treatment 150,000 - 300,000 ne
Slide 12: VEGF-2 Technology
VEGF-2 Technology What is VEGF-2 A naturally occurring growth factor that stimulates the migration and growth of endothelial cells, essential components in the development of new blood vessels How does VEGF-2 work When injected into ischemic muscle tissue, the VEGF-2 gene encodes the VEGF-2 protein
Slide 13: VEGF-2 Advantages
VEGF-2 Advantages Selective for endothelial cells Potent angiogenic factor Heparin binding Both protein and gene stimulate angiogenesis Effects are enhanced in ischemic tissue Secretory in nature Short-lived gene expression No toxicity reported in our CAD Phase I-IIa trials
Slide 14: Gene Therapy Delivery Systems
Gene Therapy Delivery Systems Naked ‘DNA’ Plasmid Delivery Non-viral vector efficiently delivers genetic material directly to the tissue where the gene transfer occurs Demonstrated minimal side effects and allows for future treatments Direct tissue injection Rapid degradation of plasmid DNA in circu
Slide 15: CAD Phase I and Phase IIA - Clinical Results
CAD Phase I and Phase IIA - Clinical Results Phase I - Mini Thoracotomy 30 Class III/IV angina patients injected directly into myocardium Positive clinical results 74% patients reported a reduction in angina of greater than 2 classes Significant reduction in episodes of angina from 31 to 9 per week
Slide 16: Phase I Clinical Results: CCS Class Angina
Phase I Clinical Results: CCS Class Angina CCS Class Angina Decrease in Angina Class > 2 Baseline 0.5 1 2 3 12 24 Time after VEGF-2 Injection (Months) Published in The American Journal of Cardiology, August 15, 2003 p<0.05
Slide 17: CAD Physician Advisors
CAD Physician Advisors Douglas W. Losordo, M.D. – National Principal Investigator Involved in therapeutic angiogenesis research for 20+ years Chief, Cardiovascular Research St. Elizabeth’s Medical Center Associate Professor of Medicine Tufts University School of Medicine Editorial Board, Circulation
Slide 18: GENASIS Phase IIb Clinical Trial Design
GENASIS Phase Ilb Clinical Trial Design National multi-center, double-blind, dose ranging N = 404, four cohorts (0, 20mg, 200mg, 800mg) Class III and IV angina “no op” patients Boston Scientific StilettoTM catheter Efficacy data measured at 3 months, safety data at 1 year 20 clinical sites in the Un
Slide 19: Representative Clinical Trial Sites
Representative Clinical Trial Sites Caritas St. Elizabeth’s Medical Center Scripps Green Hospital Minneapolis Heart Washington Heart Rush University Medical Center Fuqua Heart Center Arizona Heart Institute Texas Heart Institute Columbia Presbyterian Duke Medical Center Mayo Clinic Mayo Clinic SW Fl
Slide 20: Keys to Success for GENASIS trial
Keys to Success for GENASIS trial Choosing the right gene – VEGF-2 Choosing the best vector – Naked plasmid DNA Choosing the best delivery strategy – Intramyocardial injection Choosing the appropriate patient population – Class III / IV refractory angina Choosing the right clinical investigators and
Slide 21: Conclusion
Conclusion “Later-stage” therapeutic serving multiple unmet medical needs Support of key opinion leaders $1 billion estimated US annual market opportunity for Refractory CAD Major collaboration with Boston Scientific Corporation Strong intellectual property position Commenced manufacturing of Phase
Slide 22: Contact
75 Fifth Street, NW Suite 313 Atlanta, GA 30308 404.526.6200 www.corautus.com Richard E. Otto President and CEO
Corautus Genetics — Roth Capital Partners New York Conference 2004 on 6ix